Rho Kinase Inhibition with Fasudil in the SOD1(G93A) Mouse Model of Amyotrophic Lateral Sclerosis—Symptomatic Treatment Potential after Disease Onset

Despite an improved understanding of the genetic background and the pathomechanisms of amyotrophic lateral sclerosis (ALS) no novel disease-modifying therapies have been successfully implemented in clinical routine. Riluzole still remains the only clinically approved substance in human ALS treatment...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Pharmacol
Autors principals: Günther, René, Balck, Alexander, Koch, Jan C., Nientiedt, Tobias, Sereda, Michael, Bähr, Mathias, Lingor, Paul, Tönges, Lars
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2017
Matèries:
Pharmacology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5281550/
https://ncbi.nlm.nih.gov/pubmed/28197100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00017
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars